Tom Donovan
Profile
Tom Donovan worked as a Communications Director at Nexvet Biopharma Plc and Nexvet Australia Pty Ltd.
He received undergraduate and graduate degrees from Auckland University.
Former positions of Tom Donovan
| Companies | Position | End |
|---|---|---|
Nexvet Australia Pty Ltd.
 Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Public Communications Contact | 28/02/2017 |
| NEXVET BIOPHARMA PUBLIC LIMITED CO | Public Communications Contact | - |
Training of Tom Donovan
| Auckland University | Graduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Nexvet Australia Pty Ltd.
Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Nexvet Biopharma Plc
 Nexvet Biopharma Plc Pharmaceuticals: MajorHealth Technology Nexvet Biopharma Plc engaged in the provision of integrated biopharmaceutical business. It focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. The company was founded in September 2014 and was headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Tom Donovan
